Genmab — Januar 2022

[Solsen]

Genmab and Synaffix Enter into License Agreement for ADC Technology
Media Release

Synaffix to provide access to proprietary antibody-drug conjugate (ADC) technologies
Genmab secures rights for conducting research on ADCs against multiple drug targets with options for exclusive worldwide development and commercialization of resulting therapies
Synaffix to receive an upfront payment of USD $4.5 million with a total deal value of up to USD $415 million plus tiered single digit royalties on sales

[BioShare]

Genmab og Synaffix indgår aftale om ADC.

[BioShare]

https://ir.genmab.com/news-releases/news-release-details/genmab-and-synaffix-enter-license-agreement-adc-technology

[ProinvestorNEWS]

Genmab and Synaffix Enter into License Agreement for ADC Technology https://www.proinvestor.com/investornyt/758658/genmab-and-synaffix-enter-into-license-agreement-for-adc-technology

[Sukkeralf]

site specific conjugation bl.a.

[E_L]

bl.a. ?

[Mcjean]

onder andere

[E_L]

ok

[E_L]

it isn't that long ago that Jan told us how impressed he was with AbbVie ADC technology, calling it ADC 3.0 ... things change fast i guess

[E_L]

Synaffix even partnered with ADCT ...

https://synaffix.com/

[E_L]

https://www.fiercebiotech.com/biotech/415m-line-genmab-taps-synaffix-for-antibody-drug-conjugate-technologies With $415M on the line, Genmab taps Synaffix for antibody-drug conjugate technologies

[troldmanden]

Det er ikke helt klart om de $415 mio er per target/antistof, eller om det er den øvre grænse for max x projekter

[BioShare]

Det er "total potential deal value" + "tired mid-single digits royalty".

[troldmanden]

ja men vi ved ikke hvor mange targetes der er tale om. Men egentligt kunne man (læs mig selv) også sige sig selv at der er tale om flere aftaler til det beløb. For der bliver ikke indgået SÅ store deals på enkelt target/antistof der først nu skal startes op. Altså bliver det ikke mere earlystage end det her

[troldmanden]

Så vi taler nok 3-5 targets i alt

[ProinvestorNEWS]

Genmab indgår lincensaftale med Synaffix om ADC-teknologi - NY https://www.proinvestor.com/investornyt/758686/genmab-indgar-lincensaftale-med-synaffix-om-adc-teknologi-ny

[Sukkeralf]

trold tænker nok mere 2-3 targets, men igen lidt svært at vurdere ud fra en lidt kringlet tekst

[troldmanden]

Sukker jeg tror det er flere targets. De betaler ikke plus $200 mio for en forsknings aftale. Det var sådan en aftale JnJ betale $20 mio per target på den gamle aftale

[troldmanden]

Bemærk genmab står for alle udgifter. Det koster på royaltieses og milstones

[Sukkeralf]

Janssen betaler 170 og 190 millioner dollars pr target (DuoBody).